These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34390951)

  • 1. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N; Vaknin-Dembinsky A
    J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
    J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
    [No Abstract]   [Full Text] [Related]  

  • 3. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective study.
    Monif M; Sequeira RP; Muscat A; Stuckey S; Sanfilippo PG; Minh V; Loftus N; Voo V; Fazzolari K; Moss M; Maltby VE; Nguyen AL; Wesselingh R; Seery N; Nesbitt C; Baker J; Dwyer C; Taylor L; Rath L; Van der Walt A; Marriott M; Kalincik T; Lechner-Scott J; O'Brien TJ; Butzkueven H
    Clin Immunol; 2024 Aug; 265():110304. PubMed ID: 38964633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Li H; Zhang X
    N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
    [No Abstract]   [Full Text] [Related]  

  • 8. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
    De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
    Seferoğlu M; Ethemoğlu Ö; Turan ÖF; Siva A
    Neurol Sci; 2021 Sep; 42(9):3533-3535. PubMed ID: 34165650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.
    Paul F
    Expert Opin Pharmacother; 2013 Jan; 14(1):1-3. PubMed ID: 23256603
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Coss-Rovirosa F; Salado-Burbano J; Casallas-Vanegas A; Caire-Herrera LE; Gómez-Figueroa E; Flores-Rivera J
    Mult Scler Relat Disord; 2020 May; 40():101938. PubMed ID: 31982666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cladribine in the treatment of relapsing multiple sclerosis].
    Robles-Cedeno R; Ramio-Torrenta L
    Rev Neurol; 2018 Nov; 67(9):343-354. PubMed ID: 30350846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
    Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
    Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.